TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05376605

Intervention type: OTHER
Intervention: assessment
Description: Evaluations of the patients will be made with scales, questionnaires and physical tests.
Study: NCT05682365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prevANS intervention
Description: prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).
Study: NCT06121999

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care acceptance-based behavioral weight loss program
Description: Evidence-based, structured weight loss program for adults with co-morbid conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Published as a workbook for participants and a clinician guide, the intervention consists of twenty-five sessions or modules with accompanying worksheets. Each session covers specific acceptance-based behavioral skills to implement and build upon in subsequent sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care acceptance-based behavioral weight loss program
Description: Evidence-based, structured weight loss program for adults with co-morbid conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Published as a workbook for participants and a clinician guide, the intervention consists of twenty-five sessions or modules with accompanying worksheets. Each session covers specific acceptance-based behavioral skills to implement and build upon in subsequent sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy dietary and lifestyle modifications
Description: Occupational therapy Model of Human Occupation Screening Tool (MOHOST) and Role Checklist version 3 (RCv3) assessments identify areas of need for personalizing participant implementation of the standard of care acceptance-based behavioral weight loss program. Areas of need may include physical activity limitations to be addressed in an exercise plan or social determinants of health that are barriers to dietary and lifestyle modifications. Dietary and lifestyle modifications are based on American Gastroenterology Association (AGA) recommendations published in practice guidelines for this population. Recommendations include a Mediterranean diet, improved self-management of co-morbid chronic conditions, and a total body weight loss of five to ten percent at 1 - 2 pound weekly increments.
Study: NCT05944211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: The subjects will initiate treatment with 7.5 mg hetrombopag once a day, starting orally 24 hours after the end of chemotherapy. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts once every two weeks, and maximum dose should not exceed 15 mg daily. Subjects whose platelet count \<25×109/L for 2 weeks, the hetrombopag dose will be increased by 2.5mg. If subjects whose platelet count ≥100×109/L or who had received hetrombopag for 28 days, hetrombopag can be stopped. Hetrombopag Olamine is sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.~Emergency treatment: When the platelet count was less than 20×109/L, platelet transfusion was given according to the evaluation of the investigator.
Study: NCT06305988

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.
Study: NCT06165926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% hypertonic dextrose
Description: The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical therapy
Description: Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
Study: NCT05512949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JYNNEOS
Description: JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JYNNEOS
Description: JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JYNNEOS
Description: JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
Study: NCT06445374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Epinephrine
Description: 0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes).
Study: NCT05998590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein supplement
Description: The participants received a 60g protein bolus each evening prior to sleep from week 3 to week 12 of training.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate protein supplement
Description: The participants received a 20g protein bolus each evening prior to sleep from week 3 to week 12 of training.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate placebo
Description: The participants received an isocaloric carbohydrate bolus each evening prior to sleep from week 3 to week 12 of training.

Intervention type: OTHER
Group type: OTHER
Intervention: Control: No supplementation
Description: The participants did not receive any supplementation but instead acted as a control group doing BT only
Study: NCT05391048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(20mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(20mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(10mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(10mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
Study: NCT06085820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental (birth ball)
Description: It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental (birth dance)
Description: Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman.
Study: NCT05822271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthognathic Surgery
Description: Type of surgery performed to correct skeletal malocclusions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthognathic Surgery
Description: Type of surgery performed to correct skeletal malocclusions
Study: NCT04579510

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novel monovalent oral poliovirus vaccine type 2 (nOPV2)
Description: nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novel monovalent oral poliovirus vaccine type 2 (nOPV2)
Description: nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent oral poliovirus vaccine (bOPV)
Description: The live types 1 \& 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 \& 3 attenuated Polio viruses (Sabin strains).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent oral poliovirus vaccine (bOPV)
Description: The live types 1 \& 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 \& 3 attenuated Polio viruses (Sabin strains).
Study: NCT05021484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felzartamab
Description: Intravenous infusion in regular intervals over 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion in regular intervals over 6 months
Study: NCT05719831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan fumarate + high dose amoxicillin（H-10d）
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan fumarate + low dose amoxicillin（L-10d)
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
Study: NCT05067127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution of equal volume to active arm
Study: NCT05719831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vonoprazan fumarate + amoxicillin（H-14d)
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
Study: NCT05997940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG block
Description: The PENG block was performed with the patient in the supine position at preoperative waiting room. A curvilinear low-frequency ultrasound probe (2-5 MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22 gauge, 100 mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL
Study: NCT05872334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monofix
Description: a new absorbable barbed suture device
Study: NCT06311019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring and use of connected insulinpen for bolus insulin
Description: Continuous glucose monitoring (Abbott Freestyle Libre 2) and use of connected insulinpen (Novopen 6) for bolus insulin
Study: NCT05753137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture placebo
Description: A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.The control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation.
Study: NCT06435468

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample for genetic analysis
Description: genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample for immunological response assessments
Description: Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample for immunological response assessments
Description: Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample to identify relevant biomarker of the disease
Description: Research biomarkers for diagnosis, prognosis and monitoring of disease activity
Study: NCT06224894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antiemetic treatment
Description: antiemetic treatment
Study: NCT05379426

Intervention type: OTHER
Intervention: Impact COVID-19 pandemic
Description: Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
Study: NCT06435468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample to identify relevant biomarker of the disease
Description: Research biomarkers for diagnosis, prognosis and monitoring of disease activity
Study: NCT04586192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common Elements Toolbox- Adult version (COMET-A)
Description: COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self-awareness Control
Description: A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
Study: NCT05854706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: Theta Burst Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta Burst Stimulation
Description: Theta Burst Stimulation
Study: NCT05377606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy with silicone oil
Description: Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy with SF6
Description: Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
Study: NCT04691700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goreisan
Description: Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard therapy without Goreisan
Study: NCT06222593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide in combination with Sunitinib
Description: Antineoplastics, Antiandrogen; CYP3A4 Inhibitor
Study: NCT05601778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
Study: NCT06324409

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder telephone call
Description: A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)